6 Gynecological Oncology Group study,” Gynecologic Oncology, vol. 40, no. 1, pp. 55–65, 1991. [15] M. Q. Bernardini, T. May, M. A. Khalifa et al., “Evaluation of two management strategies for preoperative grade 1 endometrial cancer,” Obstetrics and Gynecology, vol. 114, no. 1, pp. 7–15, 2009. [16] The Writing Committee on Behalf of the ASTEC Study Group, “Eﬃcacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study,” The Lancet , vol. 373, no. 9658, pp. 125–136, 2009. [17] D. S. Mohan, M. A. Samuels, M. A. Selim et al., “Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma,” Gynecologic Oncology, vol. 70, no. 2, pp. 165–171, 1998. [18] C. V. Lutman, L. J. Havrilesky, J. M. Cragun et al., “Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology,” Gynecologic Oncology, vol. 102, no. 1, pp. 92–97, 2006. [19] J. M. Cragun, L. J. Havrilesky, B. Calingaert et al., “Retrospec- tive analysis of selective lymphadenectomy in apparent early- stage endometrial cancer,” Journal of Clinical Oncology, vol. 23, no. 16, pp. 3668–3675, 2005. [20] A. Mariani, S. C. Dowdy, W. A. Cliby et al., “Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging,” Gynecologic Oncology, vol. 109, no. 1, pp. 11–18, 2008. [21] P. B. Panici, S. Basile, F. Maneschi et al., “Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial,” Journal of the National Cancer Institute, vol. 100, no. 23, pp. 1707–1716, 2008. [22] P. Uharcˇek, “Prognostic factors in endometrial carcinoma,” Journal of Obstetrics and Gynaecology Research, vol. 34, no. 5, pp. 776–783, 2008. [23] J. I. Sorosky, “Endometrial cancer,” Obstetrics and Gynecology, vol. 11, pp. 436–447, 2008. [24] C. Goudge, S. Bernhard, N. G. Cloven, and P. Morris, “The impact of complete surgical staging on adjuvant treatment decisions in endometrial cancer,” Gynecologic Oncology, vol. 93, no. 2, pp. 536–539, 2004. [25] I. Ben-Shachar, J. Pavelka, D. E. Cohn et al., “Surgical staging for patients presenting with grade 1 endometrial carcinoma,” Obstetrics and Gynecology, vol. 105, no. 3, pp. 487–493, 2005. [26] J. K. Chan, V. Loizzi, M. Youssef et al., “Signiﬁcance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium,” Gynecologic Oncology, vol. 90, no. 1, pp. 181–185, 2003. [27] S. F. Lax, R. J. Kurman, E. S. Pizer, L. Wu, and B. M. Ronnett, “A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility com- pared with FIGO grading and identiﬁes subsets of advance- stage tumors with favorable and unfavorable prognosis,” American Journal of Surgical Pathology, vol. 24, no. 9, pp. 1201– 1208, 2000. [28] A. Alkushi, Z. H. Abdul-Rahman, P. Lim et al., “Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems,” American Journal of Surgical Pathology, vol. 29, no. 3, pp. 295–304, 2005. [29] K. Kinkel, Y. Kaji, K. K. Yu et al., “Radiologic staging in patients with endometrial cancer: a meta-analysis,” Radiology, vol. 212, no. 3, pp. 711–718, 1999. Obstetrics and Gynecology International [30] J.-Y. Park, E. N. Kim, D.-Y. Kim et al., “Comparison of the validity of magnetic resonance imaging and positron emis- sion tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer,” Gynecologic Oncology, vol. 108, no. 3, pp. 486–492, 2008. [31] L. Savelli, M. Ceccarini, M. Ludovisi et al., “Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging,” Ultrasound in Obstetrics and Gynecology, vol. 31, no. 5, pp. 560–566, 2008. [32] F. Girardi, E. Petru, M. Heydarfadai, J. Haas, and R. Win- ter, “Pelvic lymphadenectomy in the surgical treatment of endometrial cancer,” Gynecologic Oncology, vol. 49, no. 2, pp. 177–180, 1993. [33] G. H. Eltabbakh, “Intraoperative clinical evaluation of lymph nodes in women with gynecologic cancer,” American Journal of Obstetrics and Gynecology, vol. 184, no. 6, pp. 1177–1181, 2001. [34] H. A. Arango, M. S. Hoﬀman, W. S. Roberts, S. L. Decesare, J. V. Fiorica, and J. Drake, “Accuracy of lymph node palpation to determine need for lymphadenectomy in gynecologic malignancies,” Obstetrics and Gynecology, vol. 95, no. 4, pp. 553–556, 2000. [35] P. Baker and E. Oliva, “A practical approach to intraoperative consultation in gynecological pathology,” International Jour- nal of Gynecological Pathology, vol. 27, no. 3, pp. 353–365, 2008. [36] A. S. Case, R. P. Rocconi, J. M. Straughn Jr. et al., “A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer,” Obstetrics and Gynecology, vol. 108, no. 6, pp. 1375–1379, 2006. [37] M. Frumovitz, B. M. Slomovitz, D. K. Singh et al., “Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer,” Journal of the American College of Surgeons, vol. 199, no. 3, pp. 388–393, 2004. [38] A. Papadia, G. Azioni, B. Brusaca` et al., “Frozen section underestimates the need for surgical staging in endometrial cancer patients,” International Journal of Gynecological Cancer, vol. 19, no. 9, pp. 1570–1573, 2009. [39] G. Pristauz, A. A. Bader, P. Regitnig, J. Haas, R. Winter, and K. Tamussino, “How accurate is frozen section histology of pelvic lymph nodes in patients with endometrial cancer?” Gynecologic Oncology, vol. 115, no. 1, pp. 12–17, 2009. [40] Z. Holub, A. Jabor, and L. Kliment, “Comparison of two procedures for sentinel lymph node detection in patients with endometrial cancer: a pilot study,” European Journal of Gynaecological Oncology, vol. 23, no. 1, pp. 53–57, 2002. [41] T. W. Burke, C. Levenback, C. Tornos, M. Morris, J. T. Wharton, and D. M. Gershenson, “Intraabdominal lym- phatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study,” Gynecologic Oncology, vol. 62, no. 2, pp. 169–173, 1996. [42] M. L. Echt, M. A. Finan, M. S. Hoﬀman, R. C. Kline, W. S. Roberts, and J. V. Fiorica, “Detection of sentinel lymph nodes with lymphazurin in cervical, uterine, and vulvar malignancies,” Southern Medical Journal, vol. 92, no. 2, pp. 204–208, 1999. [43] E. Pelosi, V. Arena, B. Baudino et al., “Preliminary study of sentinel node identiﬁcation with 99mTc colloid and blue dye in patients with endometrial cancer,” Tumori, vol. 88, no. 3, pp. S9–S10, 2002.